Publication | Closed Access

Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial

MedicineConcept Clinical TrialAntiviral Drug DevelopmentAntiviral TherapyPharmacotherapyLethal Mouse ModelAntiviral DrugPharmacologyAntiviral CompoundSchedule-dependent Protective Efficacy